Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association

Neal J. Weinreb, Pramod K. Mistry, Barry E. Rosenbloom, Madhav V. Dhodapkar

Blood (2018) 131 (22): 2500–2501.

https://doi.org/10.1182/blood-2018-02-834689

Published: 2018

Journal Articles

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Pramod Mistry, MD PhD FRCP, Neal J. Weinreb, MD FACP, Julie Batista, ScM, ScD, Hans C. Andersson, MD, Manisha Balwani, MD MS, Thomas Andrew Burrow, MD, Joel Charrow, MD, Paige Kaplan, MB, BCh, Aneal Khan, MD MSc, FCCMG, FRCPC, Priya S. Kishnani, MD MB BS, Edwin H. Kolodny, MD, Barry E. Rosenbloom, MD, C. Ronald Scott, MD

Blood (2016) 128 (22): 4877.

https://doi.org/10.1182/blood.V128.22.4877.4877

Published: 2016

Journal Articles

Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results

Barry E. Rosenbloom, MD, Timothy M. Cox, MD, Guillermo I. Drelichman, MD, Renata Cravo, MD, Manisha Balwani, MD MS, Thomas Andrew Burrow, MD FAAP, FACMG, Ana Maria Martins, MD PhD, Elena Lukina, MD PhD, Leorah H. Ross, MD PhD, Jennifer Angell, ScM, Judith Peterschmitt, MD

Blood (2014) 124 (21): 1406.

https://doi.org/10.1182/blood.V124.21.1406.1406

Published: 2014

Journal Articles

Evaluation of Disease Burden and Response to Treatment in Adults with Type 1 Gaucher Disase Using a Validated DS3 Severity Score Index

Neal J. Weinreb, MD FACP, Eleanor Feingold, PhD, Suma Shankar, MD PhD, Barry E. Rosenbloom, MD, David Finegold, MD, PhD

Blood (2014) 124 (21): 4957.

https://doi.org/10.1182/blood.V124.21.4957.4957

Published: 2014

Journal Articles

Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals

Thomas Andrew Burrow, MD, FAAP, FACMG, Manisha Balwani, MD, MS, Timothy M. Cox, MD, Guillermo Drelichman, MD, Renata Cravo, MD, Ana Maria Martins, MD, PhD, Elena Lukina, MD, PhD, Barry E. Rosenbloom, MD, Leorah H. Ross, MD, PhD, Jennifer Angell, ScM, Ana Cristina Puga, MD, PhD

Blood (2013) 122 (21): 3468.

https://doi.org/10.1182/blood.V122.21.3468.3468

Published: 2013

Journal Articles

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

Gregory M Pastores, Barry E Rosenbloom, MD, Neal J Weinreb, Ozlem Goker-Alpan, Rebecca Mardach, Mark Lipson, Jennifer Ibrahim, Gabriel M Cohn, David Zahrieh, Pramod K Mistry

Blood (2011) 118 (21): 1101.

https://doi.org/10.1182/blood.V118.21.1101.1101

Published: 2011

Journal Articles

Thrombocytopenia in the Absence of Splenomegaly in Patients with Type 1 Gaucher Disease: A Preliminary Analysis From the ICGG Gaucher Registry,

Barry E Rosenbloom, MD, Sarah Kulke, MD, John Taylor, Neal J. Weinreb, MD

Blood (2011) 118 (21): 4217.

https://doi.org/10.1182/blood.V118.21.4217.4217

Published: 2011

Journal Articles

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Maria D. Cappellini, MD, Nadia Belmatoug, Alex Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, MD, Anna Tylki-Szymañska, Neal J. Weinreb, MD, Ari Zimran, MD, Carla Hollak, MD, PhD

Blood (2010) 116 (21): 4719.

https://doi.org/10.1182/blood.V116.21.4719.4719

Published: 2010

Journal Articles

Gaucher disease and cancer incidence: a study from the Gaucher Registry

Barry E. Rosenbloom, Neal J. Weinreb, Ari Zimran, Katherine A. Kacena, Joel Charrow, Elizabeth Ward

Blood (2005) 105 (12): 4569–4572.

https://doi.org/10.1182/blood-2004-12-4672

Published: 2005

NARROW

MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results

Evaluation of Disease Burden and Response to Treatment in Adults with Type 1 Gaucher Disase Using a Validated DS3 Severity Score Index

Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

Thrombocytopenia in the Absence of Splenomegaly in Patients with Type 1 Gaucher Disease: A Preliminary Analysis From the ICGG Gaucher Registry,

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Gaucher disease and cancer incidence: a study from the Gaucher Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only